MAIAHIGH SIGNALFINANCIAL10-K

MAIA shows severe financial deterioration with R&D expenses plummeting 95.5% while operating losses worsened significantly, indicating potential funding constraints forcing dramatic cost cuts.

The massive reduction in R&D spending from $10.0M to $454K suggests the company may be running out of cash and cutting core research activities, which is particularly concerning for a clinical-stage biotech. The worsening operating losses despite dramatic cost cuts, combined with declining stockholders' equity and increased liabilities, points to serious liquidity issues that could threaten the company's ability to continue operations.

Comparing 2026-03-23 vs 2025-03-21View on EDGAR →
FINANCIAL ANALYSIS

MAIA's financials show a company in severe distress, with R&D expenses collapsing 95.5% from $10.0M to $454K while operating losses still worsened by 43.1% to -$24.3M, indicating cuts weren't enough to stem losses. The balance sheet deteriorated with stockholders' equity declining 34.6% and current liabilities spiking 52.4%, while operating cash flow worsened by 20% to -$18.8M. This combination of dramatic cost-cutting in core R&D activities alongside worsening losses and cash burn suggests a liquidity crisis that threatens the company's viability as a going concern.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-99.2%
$7K→57

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-95.5%
$10.0M→$454K

R&D spending cut 95.5% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+52.4%
$3.8M→$5.8M

Current liabilities surged 52.4% — significant near-term obligations; verify ability to meet short-term debt.

Operating Income
P&L
-43.1%
-$17.0M→-$24.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Stockholders Equity
Balance Sheet
-34.6%
$3.6M→$2.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-20%
-$15.7M→-$18.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Liabilities
Balance Sheet
+12.4%
$6.5M→$7.3M

Liabilities increased 12.4% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-21
ADDED
In some cases, forward-looking statements may be identified by words such as believe, may, will, estimate, continue, anticipate, intend, could, would, expect, objective, plan, potential, seek, grow, target, if, and similar expressions intended to identify forward-looking statements.
(MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.
Ateganosine (THIO, 6-thio-dG or 6-thio-2 -deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
In the trial, patients with advanced NSCLC are treated first with ateganosine followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
In July 2025, we initiated an expansion of the THIO-101 trial focused on third-line NSCLC patients who are resistant to checkpoint inhibitors and chemotherapy.
+7 more — sign up free →
REMOVED
In some cases, forward-looking statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "expect," "objective," "plan," "potential," "seek," "grow," "target," "if," and similar expressions intended to identify forward-looking statements.
We will need substantial additional funding, which may not be available on acceptable terms, or at all.
Our Company We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.
THIO (6-thio-dG or 6-thio-2 -deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →